Viking Therapeutics, Inc. (VKTX) is a leading biotherapeutics company engaged in developing treatments for metabolic and endocrine diseases. VK2809 is a lad candidate of the company in Phase 2 trials for treating biopsy-confirmed non-alcoholic steatohepatitis. VK0214 is in Phase 1 trials for treating X-linked adrenoleukodystrophy. VK2735 is in Phase 1 trials for treating metabolic disorders.
The price of VKTX stock during the regular trading on January 31, 2022, was last checked to be $3.69 with a surge of 3.07%.
VKTX: Events and Happenings
On January 24, 2022, VKTX reported about the clinical hold placed by FDA on its lead candidate VK0214. FDA had demanded supplementary preclinical data before the continuation of Phase 1b trials. The company is likely to provide the data in Q2 2022.
On January 10, 2022, VKTX reported about the commencement of Phase 1 clinical trials for its lead candidate VK2735. On January 3, 2022, VKTX reported that the company’s Executives presented at H.C. Wainwright BioConnect 2022 Conference held on January 10-13, 2022. On November 9, 2021, VKTX reported that the company’s Executives presented at the Virtual Stifel 2021 Healthcare Conference held on November 15-17, 2021.
VKTX: Key Financials
On November 3, 2021, VKTX reported its financial results for the third quarter ended September 30, 2021. Some of the key updates are as follows.
Net Loss per Share
Basic and diluted net loss per share in Q3 2021 $13.2 million or $0.17 against $9.3 million or $0.13 for the corresponding period in 2020.
Assets
Total current assets in Q3 2021 were $224.2 million.
On November 1, 2021, VKTX reported about the presentation of preclinical results from internally developed dual agonists study at the Virtual ObesityWeek 2021 held on November 1-5, 2021.
Conclusion
VKTX stock down performed 39% from the last six months due to the impact of the pandemic on the economy. The current market increase is the outcome of uncertain factors contributing positively to the company’s stock. As the company has shown no recent activity, the financial experts are attributing this gain in stock to the company’s strategies.
